🟢 Tempus AI is trading 10.29% up today as Moderna vaccine results strengthen Personalis deal confidence

Tempus AI is trading $67.55 (+10.29%) as investors connect positive Phase 3 results for Moderna’s personalized cancer vaccine with Personalis, which Tempus AI agreed to acquire for $1.5 billion.

• On August 19, 2026, shares closed at $61.25, up 24.09%, extending that rally.
• Personalis-linked sequencing technology supported the vaccine program, strengthening confidence in the acquisition’s strategic value.
• The move is notable as broader U.S. markets are lower amid rising Treasury yields.